Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Contingent Liabilities and Commitments (Details Textual)

v3.8.0.1
Contingent Liabilities and Commitments (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Aug. 31, 2017
Mar. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Statement Line Items [Line Items]        
Accrued payments     $ 250  
Cipher [Member]        
Statement Line Items [Line Items]        
Royalty payments, percentage   16.50%    
CKD [Member]        
Statement Line Items [Line Items]        
Upfront payments $ 500     $ 500
Upfront payments, additional       $ 2,500
Royalty payments, percentage       23.00%
Top of range [Member]        
Statement Line Items [Line Items]        
Percentage of net sales     3.00%  
Bottom of range [Member]        
Statement Line Items [Line Items]        
Percentage of net sales     2.00%  
Euro [Member]        
Statement Line Items [Line Items]        
Concession commission     $ 25  
Annual royalties     10  
Total royalties     $ 850  
Patent agreement, description     The patent under the agreement, as follows: (i) € 50 thousand upon initiation of Phase I studies; (ii) € 100 thousand upon initiation of Phase II studies; (iii) € 200 thousand upon initiation of Phase III studies; and (iv) € 500 thousand upon marketing approval by any regulatory authority.  
Royalty payments, percentage     10.00%  
NIS [Member]        
Statement Line Items [Line Items]        
Accrued payments     $ 867  
Lease expenses     222 $ 195
Payment of award expenses     50  
Personal damages     73  
Damages claims     $ 125,000  
NIS [Member] | Cipher [Member]        
Statement Line Items [Line Items]        
Upfront payments   $ 5,141    
NIS [Member] | CKD [Member]        
Statement Line Items [Line Items]        
Upfront payments       $ 1,901
CAD [Member] | Cipher [Member]        
Statement Line Items [Line Items]        
Upfront payments   1,650    
Upfront payments, additional   $ 2,000